Published in Br J Cancer on February 01, 1980
The response to chemotherapy of a variety of human tumour xenografts. Br J Cancer (1983) 1.53
Human tumour xenografts: a critical appraisal. Br J Cancer Suppl (1980) 1.08
Colony growth and clonogenic cell survival in human melanoma xenografts treated with chemotherapy. Br J Cancer (1980) 1.05
Quantitation of drug sensitivity by human metastatic melanoma colony-forming units. Br J Cancer (1981) 0.96
Role of laboratory chemosensitivity testing in the selection of cancer chemotherapy for individual patients. J Clin Pathol (1981) 0.82
Variations in exposure to mitomycin C in an in vitro colony-forming assay. Br J Cancer (1986) 0.81
Clonogenic cell survival in cryopreserved human tumour cells. Br J Cancer (1981) 0.80
The spectrum of chemosensitivity of two human pancreatic carcinoma xenografts. Br J Cancer (1982) 0.78
Chemosensitivity of human head and neck cancer xenografts in the clonogenic assay and in nude mice. Br J Cancer (1986) 0.75
Improved immune-suppression techniques for the exongrafting of human tumours. Br J Cancer (1978) 4.28
An in vitro colony assay for human tumours grown in immune-suppressed mice and treated in vivo with cytotoxic agents. Br J Cancer (1978) 3.82
A colony-forming assay for human tumour xenografts using agar in diffusion chambers. Br J Cancer (1976) 2.11
Variation in response of xenografts of colo-rectal carcinoma to chemotherapy. Br J Cancer (1978) 1.77
Chemotherapy of human colon cancer xenografts in athymic nude mice. Cancer (1977) 1.39
Human tumour xenografts established and serially transplanted in mice immunologically deprived by thymectomy, cytosine arabinoside and whole-body irradiation. Br J Cancer (1980) 1.31
High dose melphalan and non-cryopreserved autologous bone marrow treatment of malignant melanoma and neuroblastoma. Exp Hematol (1979) 1.13
Assays of drug sensitivity for cells from human tumours: in vitro and in vivo tests on a xenografted tumour. Br J Cancer (1979) 0.96
Evaluation of single-agent therapy in human colorectal tumour xenografts. Br J Cancer (1978) 0.93
Physiologic disposition of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (Me CCNU) in man. Cancer (1973) 0.83
Improved immune-suppression techniques for the exongrafting of human tumours. Br J Cancer (1978) 4.28
Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation. Lancet (1980) 4.21
Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer (1998) 3.93
The therapeutic response of three human tumor lines maintained in immune-suppressed mice. Cancer Res (1975) 3.50
Stem-cell survival and tumor control in the Lewis lung carcinoma. Cancer Res (1975) 3.04
Analysis of the cell population kinetics of transplanted tumours of widely-differing growth rate. Br J Cancer (1966) 2.88
In vitro and in vivo radiosensitivity of human tumour cells obtained from a pancreatic carcinoma xenograft. Nature (1976) 2.77
The growth kinetics of xenografts of human colorectal tumours in immune deprived mice. Br J Cancer (1975) 2.71
Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys (1979) 2.63
Automated collection of quality-of-life data: a comparison of paper and computer touch-screen questionnaires. J Clin Oncol (1999) 2.59
Cell proliferation studies in the intestinal epithelium of the rat. I. Determination of the kinetic parameters. Exp Cell Res (1965) 2.50
Cell loss as a factor in the growth rate of human tumours. Eur J Cancer (1967) 2.41
The development of a method for assessing the quality of life of cancer patients. Br J Cancer (1984) 2.23
Intensive treatment of multiple myeloma and criteria for complete remission. Lancet (1989) 2.04
Parenteral acyclovir therapy for herpesvirus infections in man. Lancet (1979) 1.99
Computer-based quality of life questionnaires may contribute to doctor-patient interactions in oncology. Br J Cancer (2002) 1.98
Cancer in old age--is it inadequately investigated and treated? BMJ (1999) 1.95
Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res (2000) 1.88
Non-surgical management of early breast cancer in the United Kingdom: radiotherapy fractionation practices. Clinical Audit Sub-committee of the Faculty of Clinical Oncology, Royal College of Radiologists, and the Joint Council for Clinical Oncology. Clin Oncol (R Coll Radiol) (1995) 1.82
The impact of nausea and vomiting upon quality of life measures. Br J Cancer Suppl (1992) 1.81
In vitro studies of cell proliferation in tumours. I. Critical appraisal of methods and theoretical considerations. Eur J Cancer (1965) 1.79
Variation in response of xenografts of colo-rectal carcinoma to chemotherapy. Br J Cancer (1978) 1.77
The growth and therapeutic response of human tumours in immune deficient mice. Bull Cancer (1978) 1.69
Cell proliferation studies in the intestinal epithelium of the rat. II. Theoretical aspects. Exp Cell Res (1965) 1.68
The radioresponsiveness of human tumours and the initial slope of the cell survival curve. Radiother Oncol (1984) 1.68
The human tumour xenograft--a valid model in experimental chemotherapy? Br J Surg (1980) 1.63
A comparison of methods for calculating DNA double-strand break induction frequency in mammalian cells by pulsed-field gel electrophoresis. Int J Radiat Biol (1994) 1.61
The molecular detection of circulating tumour cells. Br J Cancer (1995) 1.55
The response to chemotherapy of a variety of human tumour xenografts. Br J Cancer (1983) 1.53
The technique of labelled mitoses: analysis by automatic curve-fitting. Cell Tissue Kinet (1971) 1.51
Cell survival in B16 melanoma after treatment with combinations of cytotoxic agents: lack of potentiation. Br J Cancer (1977) 1.51
The growth rate of human tumours. Br J Cancer (1966) 1.49
Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies. Br J Cancer (1993) 1.48
Proteomics: new perspectives, new biomedical opportunities. Lancet (2000) 1.46
Growth of human tumour cell colonies from biopsies using two soft-agar techniques. Br J Cancer (1978) 1.46
The therapeutic response of bronchial carcinoma xenografts: a direct patient-xenograft comparison. Br J Cancer Suppl (1980) 1.44
Novel urothelium specific gene expression identified by differential display reverse transcriptase-polymerase chain reaction. J Urol (2006) 1.40
Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene Ther (2009) 1.40
Effect of cell density on the expression of adhesion molecules and modulation by cytokines. Cytometry (1995) 1.39
Quantitative techniques for study of the anatomy and function of small blood vessels in tumors. J Natl Cancer Inst (1969) 1.39
The cell cycle in tumours: an examination of data gained by the technique of labelled mitoses. Cell Tissue Kinet (1972) 1.34
Human tumour xenografts established and serially transplanted in mice immunologically deprived by thymectomy, cytosine arabinoside and whole-body irradiation. Br J Cancer (1980) 1.31
Influence of biogenic amines on the growth of xenografted human colorectal carcinomas. Br J Cancer (1979) 1.31
Rasch analysis of the dimensional structure of the Hospital Anxiety and Depression Scale. Psychooncology (2006) 1.30
Growth kinetics of human large bowel cancer growing in immune-deprived mice and some chemotherapeutic observations. Cancer (1975) 1.28
The immune system--is it relevant to cancer development, progression and treatment? Clin Oncol (R Coll Radiol) (2007) 1.24
Influence of tumour size on hypoxic fraction and therapeutic sensitivity of Lewis lung tumour. Br J Cancer (1977) 1.24
Influence of tumour size on radiosensitization by misonidazole. Br J Cancer Suppl (1978) 1.24
Feasibility and compliance of automated measurement of quality of life in oncology practice. J Clin Oncol (2003) 1.22
miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. Br J Cancer (2013) 1.21
Uroplakin gene expression by normal and neoplastic human urothelium. Am J Pathol (1998) 1.21
Improving the accuracy of pre-operative survival prediction in renal cell carcinoma with C-reactive protein. Br J Cancer (2010) 1.18
Tumor size dependency in the radiation response of the Lewis lung carcinoma. Cancer Res (1975) 1.16
Delayed uptake by tumours of tritium from thymidine. Nature (1966) 1.16
Social problems in oncology. Br J Cancer (2002) 1.15
Chemotherapy of human breast-carcinoma xenografts. Br J Cancer (1980) 1.15
Evidence for the existence of a novel pregnancy-associated soluble variant of the vascular endothelial growth factor receptor, Flt-1. Mol Hum Reprod (1998) 1.15
The potential use of laser capture microdissection to selectively obtain distinct populations of cells for proteomic analysis--preliminary findings. Electrophoresis (1999) 1.15
Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol (1987) 1.11
Granulocytic sarcoma: a diagnosis to be considered in unusual lymphoma syndromes. Postgrad Med J (1987) 1.10
Identification of genes involved in human urothelial cell-matrix interactions: implications for the progression pathways of malignant urothelium. Cancer Res (2001) 1.10
Dose-rate effects and the repair of radiation damage. Radiother Oncol (1986) 1.09
Human tumour xenografts: a critical appraisal. Br J Cancer Suppl (1980) 1.08
Development and evaluation of an instrument to assess social difficulties in routine oncology practice. Qual Life Res (2005) 1.06
Colony growth and clonogenic cell survival in human melanoma xenografts treated with chemotherapy. Br J Cancer (1980) 1.05
A simple method for culturing myeloma cells from human bone marrow aspirates and peripheral blood in vitro. Br J Haematol (1988) 1.04
The growth and cell population kinetics of spontaneous tumours in domestic animals. Br J Cancer (1969) 1.04
Combined radiotherapy--chemotherapy of Lewis lung carcinoma. Int J Radiat Oncol Biol Phys (1978) 1.04
The expression of early and late damage after thoracic irradiation: a comparison between CBA and C57B1 mice. Radiat Res (1983) 1.04
Molecular detection of low-level disease in patients with cancer. J Pathol (2000) 1.04
Enhancement by cytotoxic agents of artificial pulmonary metastasis. Br J Cancer (1977) 1.03
DNA strand break rejoining defect in xrs-6 is complemented by transfection with the human Ku80 gene. Cancer Res (1995) 1.03
Characterization of four new cell lines derived from human squamous carcinomas of the uterine cervix. Cancer Res (1987) 1.02
Effects of interleukin 6 administration on platelets and haemopoietic progenitor cells in peripheral blood. Cytokine (1996) 1.02
Terminology in the description of drug-radiation interactions. Int J Radiat Oncol Biol Phys (1979) 1.02
Expression and cytokine regulation of immune recognition elements by normal human biliary epithelial and established liver cell lines in vitro. J Hepatol (1998) 1.01
Serum concentrations of soluble adhesion molecules in patients with colorectal cancer. Br J Cancer (1998) 1.01
Initial radiation-induced DNA damage in human tumour cell lines: a correlation with intrinsic cellular radiosensitivity. Br J Cancer (1994) 1.00
Treatment of advanced Hodgkin's disease with high dose melphalan and autologous bone marrow transplantation. Bone Marrow Transplant (1989) 0.97
A human testicular teratoma serially transplanted in immune-deprived mice. Br J Cancer (1979) 0.97
Tumor growth and cell kinetics in chronically hypoxic animals. J Natl Cancer Inst (1970) 0.97
A comparison of the chemosensitivity of a primary tumour and its metastases using a human tumour xenograft. Eur J Cancer (1979) 0.97
Clonogenic assays in the B16 melanoma: response to cyclophosphamide. Br J Cancer (1977) 0.97
A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation. Br J Urol (1996) 0.96
Assays of drug sensitivity for cells from human tumours: in vitro and in vivo tests on a xenografted tumour. Br J Cancer (1979) 0.96
Circulating soluble adhesion molecules E-cadherin, E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in patients with gastric cancer. Br J Cancer (1997) 0.96
Induction and rejoining of DNA double-strand breaks in human cervix carcinoma cell lines of differing radiosensitivity. Radiat Res (1988) 0.96
Development of drug resistance in a murine mammary tumour. Br J Cancer (1985) 0.96
Induced and inherent resistance to alkylating agents in human small-cell bronchial carcinoma xenografts. Br J Cancer (1984) 0.95
The acute phase protein response in patients receiving subcutaneous IL-6. Clin Exp Immunol (1995) 0.95
Soluble forms of the adhesion molecule E-cadherin in urine. J Clin Pathol (1995) 0.95
Radiosensitivity, recovery and dose-rate effect in three human glioma cell lines. Radiother Oncol (1990) 0.95
Size dependence of the response of Lewis lung tumors to BCNU. Cancer Treat Rep (1976) 0.95
Inhibition of T cell activation by normal human biliary epithelial cells. J Hepatol (1999) 0.93
Detecting social problems in cancer patients. Psychooncology (2001) 0.93
The comet moment as a measure of DNA damage in the comet assay. Int J Radiat Biol (1995) 0.92
The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol (2001) 0.92
Variability of polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicentre study. Ann Oncol (1999) 0.92